Close Menu

ASCO

The first randomized study to show a PARP inhibitor benefits advanced breast cancer patients is also a sign of the expanding utility of BRCA testing in precision medicine.

Suspicious variants were uncovered through analyses of pediatric cancer survivors from the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study.

The registry collects data on cancer genetics and aims to provide patients with access to quality NGS testing, among other things.

The agency hopes to gain data on the efficacy of BRAF targeted drugs used in sequence, and how physicians implement treatments compared to how the drugs are labelled.

Though researchers highlighted their goal of using the method to move toward a test to detect early cancers, their current data speaks only to the method's performance in late-stage cancer patients.

There are now 100 sites in the US participating in the basket study, and soon trials with similar approaches will be available in Canada and 13 other countries.

Members of the ProfiLER trial identified actionable mutations in more than half of individuals with advanced cancers, though only a fraction received targeted therapy.

Data presented at ASCO showing 76 percent of cancer patients responded to larotrectinib could lead to the availability of the first tissue-agnostic targeted drug.

The guidance includes recommendations for extended RAS mutation testing to guide anti-EGFR therapy, as well as updated endorsements for analysis of mismatch repair status.

The recommendations were developed by a working group of the AMP Clinical Practice Committee that included representatives from ACMG, ASCO, and CAP.

Pages